Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) released its earnings results on Tuesday. The company reported ($0.82) EPS for the quarter, meeting analysts’ consensus estimates of ($0.82), Zacks reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Management highlighted three-year follow-up data for FICERA in HPV-negative head and neck cancer, saying approximately one in three patients remained alive at three years—nearly double retrospective standard-of-care estimates—while maintaining a consistent safety profile.
• The pivotal FORTIFI-HN01 study remains on track for substantial enrollment by year-end, with more than 200 sites active and a planned interim analysis in mid-2027 that could support a potential accelerated approval.
• Bicara initiated the FORTIFI-FLEX study to evaluate loading and every-three-week maintenance dosing, aiming to have data available by a potential U.S. approval and support inclusion of a more convenient regimen in the product label.
• The company reported approximately $497 million in cash and marketable securities at quarter-end, providing projected runway into the first half of 2029, while warning that operating expenses will rise as pivotal-trial, manufacturing, medical-affairs, and commercial-launch investments increase.
• Leadership transitions will take effect as Ryan Cohlhepp becomes CEO and Claire Mazumdar moves to vice chair and strategic advisor; Bicara also announced new finance, operations, business, and legal leadership intended to support potential commercialization.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock traded down $3.53 during trading hours on Tuesday, reaching $24.20. The stock had a trading volume of 402,159 shares, compared to its average volume of 596,974. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -8.68 and a beta of -0.75. The business’s 50 day moving average price is $25.82 and its 200-day moving average price is $21.64. Bicara Therapeutics has a 52 week low of $9.67 and a 52 week high of $30.99.

Insider Activity

In related news, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the completion of the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,292,359.84. The trade was a 2.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 88,450 shares of company stock worth $2,366,675. Corporate insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after purchasing an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics during the 4th quarter worth $44,484,000. Vanguard Group Inc. increased its position in Bicara Therapeutics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after buying an additional 195,667 shares in the last quarter. Finally, State Street Corp increased its position in Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BCAX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Morgan Stanley upped their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Finally, Guggenheim assumed coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.